Free Trial

Xencor (XNCR) Stock Price, News & Analysis

Xencor logo
$7.74 -0.01 (-0.06%)
As of 01:36 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Xencor Stock (NASDAQ:XNCR)

Key Stats

Today's Range
$7.58
$7.88
50-Day Range
$7.52
$13.20
52-Week Range
$7.16
$27.24
Volume
243,601 shs
Average Volume
655,457 shs
Market Capitalization
$551.22 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$29.50
Consensus Rating
Moderate Buy

Company Overview

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.

Xencor Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
79th Percentile Overall Score

XNCR MarketRank™: 

Xencor scored higher than 79% of companies evaluated by MarketBeat, and ranked 211th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Xencor has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 7 buy ratings, no hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Xencor has only been the subject of 4 research reports in the past 90 days.

  • Read more about Xencor's stock forecast and price target.
  • Earnings Growth

    Earnings for Xencor are expected to grow in the coming year, from ($3.68) to ($3.64) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Xencor is -2.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Xencor is -2.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Xencor has a P/B Ratio of 0.71. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Xencor's valuation and earnings.
  • Percentage of Shares Shorted

    11.31% of the outstanding shares of Xencor have been sold short.
  • Short Interest Ratio / Days to Cover

    Xencor has a short interest ratio ("days to cover") of 9.6.
  • Change versus previous month

    Short interest in Xencor has recently increased by 3.34%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Xencor does not currently pay a dividend.

  • Dividend Growth

    Xencor does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    11.31% of the outstanding shares of Xencor have been sold short.
  • Short Interest Ratio / Days to Cover

    Xencor has a short interest ratio ("days to cover") of 9.6.
  • Change versus previous month

    Short interest in Xencor has recently increased by 3.34%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Xencor has a news sentiment score of 1.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.03 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for Xencor this week, compared to 3 articles on an average week.
  • Search Interest

    1 people have searched for XNCR on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Xencor insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $50,914.00 in company stock.

  • Percentage Held by Insiders

    Only 4.76% of the stock of Xencor is held by insiders.

  • Read more about Xencor's insider trading history.
Receive XNCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xencor and its competitors with MarketBeat's FREE daily newsletter.

XNCR Stock News Headlines

Trump Predicts Dollar Downfall
READ THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... This is what President Trump said: "Our currency is crashing and will soon no longer be the world standard, which will be our greatest defeat, frankly, in 200 years." Why Would He Say This?
Xencor Reports First Quarter 2025 Financial Results
Xencor initiated with an Outperform at William Blair
See More Headlines

XNCR Stock Analysis - Frequently Asked Questions

Xencor's stock was trading at $22.98 on January 1st, 2025. Since then, XNCR shares have decreased by 66.1% and is now trading at $7.78.
View the best growth stocks for 2025 here
.

Xencor, Inc. (NASDAQ:XNCR) posted its quarterly earnings data on Thursday, May, 8th. The biopharmaceutical company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by $0.06. Xencor's quarterly revenue was up 104.6% on a year-over-year basis.

Xencor's top institutional investors include Primecap Management Co. CA (13.72%), Vanguard Group Inc. (11.10%), Price T Rowe Associates Inc. MD (5.52%) and BVF Inc. IL (3.85%). Insiders that own company stock include Bassil I Dahiyat, John R Desjarlais, John J Kuch, Allen Yang, Nancy Valente, Celia Eckert, Alan Bruce Montgomery and Kurt A Gustafson.
View institutional ownership trends
.

Shares of XNCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Xencor investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), AUO (AUOTY) and DiamondRock Hospitality (DRH).

Company Calendar

Last Earnings
5/08/2025
Today
5/28/2025
Next Earnings (Estimated)
8/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:XNCR
Employees
280
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$29.50
High Stock Price Target
$40.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+280.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.89
Research Coverage
9 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$126.09 million
Net Margins
-232.77%
Pretax Margin
-229.85%

Debt

Sales & Book Value

Annual Sales
$127.23 million
Price / Cash Flow
N/A
Book Value
$10.99 per share
Price / Book
0.70

Miscellaneous

Free Float
66,322,000
Market Cap
$551.22 million
Optionable
Optionable
Beta
0.99

Social Links

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:XNCR) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners